Patents by Inventor Yujin Huang
Yujin Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180215778Abstract: The invention relates to a 17?-alkynyl-androst-5-ene-3?,7?,17?-triol compound essentially free of steroid side-product lacking an oxygen substituent at position 7 and processes for preparing the same.Type: ApplicationFiled: March 27, 2018Publication date: August 2, 2018Inventors: Steven K. White, Yu Ge, Yujin Huang
-
Patent number: 9994608Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?,7?,17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: GrantFiled: October 19, 2015Date of Patent: June 12, 2018Assignee: NeurMedix, Inc.Inventors: Steven K. White, Yu Ge, Yujin Huang
-
Publication number: 20180079775Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?, 7?, 17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: ApplicationFiled: October 19, 2015Publication date: March 22, 2018Inventors: Steven K. White, Yu Ge, Yujin Huang
-
Patent number: 9802976Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?,7?,17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: GrantFiled: October 19, 2015Date of Patent: October 31, 2017Assignee: NeurMedix, Inc.Inventors: Steven K. White, Yu Ge, Yujin Huang
-
Patent number: 9163059Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?,7?,17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: GrantFiled: October 30, 2012Date of Patent: October 20, 2015Assignee: NEURMEDIX INC.Inventors: Steven K. White, Yu Ge, Yujin Huang
-
Publication number: 20130066087Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?,7?,17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: ApplicationFiled: October 30, 2012Publication date: March 14, 2013Applicant: Harbor Therapeutics, Inc.Inventors: Steven K. White, Yu Ge, Yujin Huang
-
Patent number: 8309746Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?,7?,17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: GrantFiled: June 5, 2009Date of Patent: November 13, 2012Assignee: Harbor Therapeutics, IncInventors: Steven K. White, Yu Ge, Yujin Huang
-
Publication number: 20120214987Abstract: The invention relates to processes for preparing 3?-O-linked steroids including 3?-O-linked-androst-5-ene steroids and 3?-O-linked-5a-androstane steroids. In one process a 3?,4?-epoxy androst-5-en-17-one is predominately reduced at the epoxy moiety wherein reduction of the 3?,4? epoxy functional group occurs preferentially at position C4 with retention of configuration at position C3 to provide a 3?-O-linked-androst-5-ene steroid. In another process, conditions are provided for inversion of configuration of a 3?-hydroxy-androst-5-ene steroid by the Mitsunobu reaction to provide a 3?-O-linked-androst-5-ene steroid with reduced amounts of 3?,5?-cycloandrostane side-product impurities.Type: ApplicationFiled: December 15, 2011Publication date: August 23, 2012Inventors: Yu Ge, Steven K. White, Yujin Huang
-
Patent number: 8119819Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.Type: GrantFiled: April 28, 2009Date of Patent: February 21, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Richard Julius Penuliar, David Mark Wallace, Lin Zhang, Gary D. Lopaschuk, Jason R. Dyck
-
Publication number: 20100016259Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.Type: ApplicationFiled: April 28, 2009Publication date: January 21, 2010Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Richard Julius Penuliar, David Mark Wallace, Lin Zhang, Gary D. Lopaschuk, Jason R. Dyck
-
Publication number: 20090326251Abstract: The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17?-ethynyl-androst-5-ene-3?,7?,17?-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.Type: ApplicationFiled: June 5, 2009Publication date: December 31, 2009Applicant: Hollis-Eden Pharmaceuticals, Inc.Inventors: Steven K. White, Yu Ge, Yujin Huang
-
Patent number: 7524969Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.Type: GrantFiled: January 22, 2002Date of Patent: April 28, 2009Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Thomas Arrhenius, Mi Chen, Jie Fei Chang, Yujin Huang, Alex Michael Nadzan, Richard Julius Penuliar, David Mark Wallace, Lin Zhang, Gary D. Lopaschuk, Jason R. Dyck
-
Patent number: 7385063Abstract: The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration of a composition containing as an active ingredient a compound according to Formula I. In particular, the invention relates to methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the administration of a compound which inhibits malonyl-coenzyme A decarboxylase activity.Type: GrantFiled: January 22, 2002Date of Patent: June 10, 2008Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Sovouthy Tith, Masayuki Haramura, David Mark Wallace, Steve Joel Brown, Charles Stanford Harmon, Lin Zhang, Gary D. Lopaschuk, Jason R. Dyck
-
Publication number: 20080070869Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.Type: ApplicationFiled: September 14, 2007Publication date: March 20, 2008Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Nadzan, Sovouthy Tith, David Wallace, Bin Liu, Masahiro Nishimoto, Gary Lopaschuk, Jason Dyck
-
Patent number: 7279477Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.Type: GrantFiled: January 22, 2002Date of Patent: October 9, 2007Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Sovouthy Tith, David Mark Wallace, Bin Liu, Masahiro Nishimoto, Gary D. Lopaschuk, Jason R. Dyck
-
Publication number: 20050238618Abstract: The invention relates to a procedure for purifying low molecular weight polylactic acid polymers by use of reduced temperature liquid-liquid phase separation of the polymers in methanol, ethanol or isopropanol based solvents, compositions comprising the polymers and methods of using the same.Type: ApplicationFiled: April 25, 2005Publication date: October 27, 2005Inventor: Yujin Huang
-
Publication number: 20040110757Abstract: This invention is a method of treatment and prophylaxis of diseases regulatable by angiogenesis, including novel FLT-1 ligands and pharmaceutical compositions containing them, useful in the methods for the treatment and prophylaxis of these diseases, as well as intermediates and processes useful for the preparation of the compounds of the invention as claimed.Type: ApplicationFiled: September 22, 2003Publication date: June 10, 2004Inventors: Thomas Arrhenius, Yujin Huang, Lin Zhang, Rossy Serafimov, Alex Nadzan, Dominic G Spinella
-
Publication number: 20040087627Abstract: The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration of a composition containing as an active ingredient a compound according to Formula I. In particular, the invention relates to methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the administration of a compound which inhibits malonyl-coenzyme A decarboxylase activity. The present invention also includes within its scope the novel process for the preparation of certain compounds.Type: ApplicationFiled: July 21, 2003Publication date: May 6, 2004Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Sovouthy Tith, Masayuki Haramura, David Mark Wallace, Steve Joel Brown, Charles Stanford Harmon, Lin Zhang
-
Publication number: 20040082576Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.Type: ApplicationFiled: July 21, 2003Publication date: April 29, 2004Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Richard Julius Penuliar, David Mark Wallace, Lin Zhang
-
Publication number: 20040063671Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.Type: ApplicationFiled: July 21, 2003Publication date: April 1, 2004Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Sovouthy Tith, David Mark Wallace, Bin Liu, Masahiro Nishimoto